These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1466276)

  • 1. Parallel procoagulant and anticoagulant pathways for high molecular weight kininogen coagulant function.
    Olson ST; Sheffer R; Shore JD
    Agents Actions Suppl; 1992; 38 ( Pt 1)():241-8. PubMed ID: 1466276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
    Olson ST; Sheffer R; Francis AM
    Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel mechanisms of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions.
    Olson ST; Francis AM; Sheffer R; Choay J
    Biochemistry; 1993 Nov; 32(45):12148-59. PubMed ID: 8218292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
    Scott CF; Schapira M; James HL; Cohen AB; Colman RW
    J Clin Invest; 1982 Apr; 69(4):844-52. PubMed ID: 7076850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing the acceleration of human factor XIa inactivation by antithrombin III.
    Scott CF; Colman RW
    Blood; 1989 May; 73(7):1873-9. PubMed ID: 2785417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
    Holmer E; Kurachi K; Söderström G
    Biochem J; 1981 Feb; 193(2):395-400. PubMed ID: 6914196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; Colman RW
    Trans Assoc Am Physicians; 1981; 94():190-7. PubMed ID: 6979819
    [No Abstract]   [Full Text] [Related]  

  • 8. Activation of blood coagulation at heparin-coated surfaces.
    Blezer R; Fouache B; Willems GM; Lindhout T
    J Biomed Mater Res; 1997 Oct; 37(1):108-13. PubMed ID: 9335355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; James A; Silver LD; Kueppers F; James HL; Colman RW
    Biochemistry; 1982 Feb; 21(3):567-72. PubMed ID: 6175341
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of heparin on the inactivation rate of human factor XIa by antithrombin-III.
    Scott CF; Schapira M; Colman RW
    Blood; 1982 Oct; 60(4):940-7. PubMed ID: 7115961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.
    Scott CF; Silver LD; Schapira M; Colman RW
    J Clin Invest; 1984 Apr; 73(4):954-62. PubMed ID: 6561202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of inhibition of platelet calpain II by human kininogens.
    Bradford HN; Schmaier AH; Colman RW
    Biochem J; 1990 Aug; 270(1):83-90. PubMed ID: 2396995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the coagulant activity and surface binding of high molecular weight kininogen.
    Colman RW; Silver LD; Purdon AD; Chang JJ; Scott CF
    Trans Assoc Am Physicians; 1984; 97():113-23. PubMed ID: 6336014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function.
    Scott CF; Silver LD; Purdon AD; Colman RW
    J Biol Chem; 1985 Sep; 260(19):10856-63. PubMed ID: 3875612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of heparin on the inhibition of the contact system enzymes.
    Colman RW; Scott CF; Pixley RA; de la Cadena RA
    Ann N Y Acad Sci; 1989; 556():95-103. PubMed ID: 2786690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa.
    Wuillemin WA; Eldering E; Citarella F; de Ruig CP; ten Cate H; Hack CE
    J Biol Chem; 1996 May; 271(22):12913-8. PubMed ID: 8662679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III.
    Pixley RA; Schapira M; Colman RW
    Blood; 1985 Jul; 66(1):198-203. PubMed ID: 3873967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human blood coagulation factor XIa by C-1 inhibitor.
    Meijers JC; Vlooswijk RA; Bouma BN
    Biochemistry; 1988 Feb; 27(3):959-63. PubMed ID: 3259145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface.
    DeLa Cadena RA; Colman RW
    Protein Sci; 1992 Jan; 1(1):151-60. PubMed ID: 1304876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.